2-aminomethyl-1-butyl pyrrolidine | 26116-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-aminomethyl-1-butyl pyrrolidine
• 英文别名: 2-(aminomethyl)-1-n-butylpyrrolidine；2-aminomethyl-1-butylpyrrolidine；1-butyl-2-aminomethylpyrrolidine；2-aminomethyl-N-butylpyrrolidine；1-Butyl-2-aminomethylpyrrolidin；(1-Butylpyrrolidin-2-YL)methanamine
• CAS: 26116-16-5
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: VRKXUSCKISXSIH-UHFFFAOYSA-N

物化性质

• 沸点：
  193.2±8.0 °C(Predicted)
• 密度：
  0.892±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-aminomethyl-1-butyl pyrrolidine 在 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (R)-N-<(1-n-butyl-2-pyrrolidinyl)methyl>-2-methoxy-5-sulfamoylbenzamide
  参考文献：
  名称：

  Antidopaminergic effects of the stereoisomers of N-[(1-alkyl-2-pyrrolidinyl)methyl]-5-sulfamoylbenzamides and -2,3-dihydro-benzofuran-7-carboxamides

  摘要：

  The stereoisomers of some N-[(1-alkyl-2-pyrrolidinyl)methyl]5-sulfamoylbenzamides (3-8) and -2,3-dihydrobenzofuran-7-carboxamides (9-18) were prepared to compare their dopamine D2 receptor binding affinities (in vitro) and inhibitory effects on apomorphine-induced hyperactivity (in vivo). In the 1-ethyl substituted compounds of the two series, the stereoisomers with S absolute configuration at the 2-position of the pyrrolidine moiety (S enantiomer 3 and 2S diastereomers 9 and 10) were more potent in both of the above activities than those with R absolute configuration (R enantiomer 4 and 2R diastereomers 11 and 12, respectively), whereas the R enantiomer (8) was more potent than the S enantiomer (7) in the 1-n-hexyl-substituted-benzamides and the 2R diastereomers (15, 16, and 18) were more potent than the 2S diastereomers (13, 14, and 17) in the 1-n-butyl- and 1-n-hexyl-2,3-dihydrobenzofuran-7-carboxamies. It was found that the stereospecificity of the compound activities altered from the S configuration to the R configuration as the 1-alkyl side chain became longer in the two series. How these stereoisomers meet the configurational requirements to interact with the dopamine D2 receptors is also discussed.

  DOI：

  10.1021/jm00105a041

文献信息

• Benzazine compounds and pharmaceutical uses thereof
  申请人：Yoshitomi Pharmaceutical Industries, Ltd.

  公开号：US05185333A1

  公开（公告）日：1993-02-09

  A benzazine compound, a geometrical isomer of said benzazine compound, an optical isomer of said benzazine compound, and a pharmaceutically acceptable salt of said benzazine compound, said benzazine compound being represented by formula (I): ##STR1## wherein each symbol is as defined in the specification. Said benzazine compounds exhibit 5-HT.sub.3 receptor antagonistic activity, and 5-HT.sub.1A receptor and/or 5-HT.sub.2 receptor and/or dopamine D.sub.2 receptor blocking activity so that they are useful as drugs for the prophylaxis or treatment of various digestive diseases vomiting and disturbances in central nervous systems and the like. The intermediates for said benzazine compounds are also disclosed.

  一种苯嗪化合物，所述苯嗪化合物的几何异构体，所述苯嗪化合物的光学异构体，以及所述苯嗪化合物的药学可接受的盐，其中所述苯嗪化合物由式（I）表示：##STR1##其中每个符号如规范中定义。所述苯嗪化合物表现出5-HT.sub.3受体拮抗活性，以及5-HT.sub.1A受体和/或5-HT.sub.2受体和/或多巴胺D.sub.2受体阻断活性，因此它们可用作用于预防或治疗各种消化疾病、呕吐和中枢神经系统紊乱等药物。所述苯嗪化合物的中间体也被披露。
• 2-Amino, 5-carbamoyl pyridine compounds
  申请人：Science Union et Cie, Societe Francaise de Racherche Medical

  公开号：US03970661A1

  公开（公告）日：1976-07-20

  Heterocyclic amides of the formula: ##SPC1## Wherein: X is N or CH; n is O or 1 and R is ##EQU1## or ##SPC2## Wherein: R.sub.1 is hydrogen or methyl, R.sub.2 and R.sub.3 which are the same, are lower alkyl or joined together, represent a polymethylenic chain from C.sub.4 to C.sub.7 optionally including an oxygen atom, and R' is saturated or unsaturated acyclic hydrocarbon radicals from C.sub.1 to C.sub.20, cycloalkyl from C.sub.3 to C.sub.7, Ar -- A-- or Ar ##EQU2## wherein: A is a single bond or a saturated or unsaturated acyclic hydrocarbon chain from C.sub.1 to C.sub.6 optionally including an oxygen atom, and Ar and R" are aromatic, alkoxy aromatic, methlenedioxy aromatic or polymethylenedioxy aromatic. These compounds are used as medicine, especially in the treatment of gastric hypersecretion, gastroduodenal ulcers and central nervous system disorders.

  该公式的杂环酰胺为：其中：X为N或CH；n为O或1，R为其中：R.sub.1为氢或甲基，R.sub.2和R.sub.3相同，为较低的烷基或结合在一起，代表一个从C.sub.4到C.sub.7的聚甲烯链，可选地包括一个氧原子，R'为饱和或不饱和的C.sub.1到C.sub.20的无环烃基，C.sub.3到C.sub.7的环烷基，Ar -- A--或Ar其中：A为单键或从C.sub.1到C.sub.6的饱和或不饱和的无环烃链，可选地包括一个氧原子，Ar和R"为芳香族，烷氧基芳香族，亚甲二氧基芳香族或聚亚甲二氧基芳香族。这些化合物被用作药物，特别用于治疗胃酸过多、胃十二指肠溃疡和中枢神经系统疾病。
• Potential neuroleptic agents, N-((2-pyrrolidinyl)methyl)-2,3-dihydrobenzofuran-7-carboxamide derivatives.
  作者：Tetsuya TAHARA、Kiyoharu HAYANO、Shu MURAKAMI、Takemi FUKUDA、Michihide SETOGUCHI、Kuniki IKEDA、Nobuhiro MARUBAYASHI

  DOI：10.1248/cpb.38.1609

  日期：——

  methamphetamine lethality in rats than 1, while it was as weak in inhibitory activity of apomorphine-induced stereotype in rats (ED50 greater than 500 mg/kg, p.o.) as 1. On the other hand, N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methyl-5-methylthio-2, 3-dihydrobenzofuran-7-carboxamide (30) showed a classical neuroleptic profile with a potency comparable to haloperidol in antagonistic activity on apomorphine-induced

  合成了一系列具有稳定分子内氢键的2,3-二氢苯并呋喃-7-羧酰胺，并在药理学模型中评估了其抗精神病活性。其中，N-[（（1-丁基-2-吡咯烷基）甲基] -2-甲基-5-氨磺酰基-2，3-二氢苯并呋喃-7-羧酰胺（15）显示出与sulpiride（1 ）和比1更高的亲脂性。化合物15对阿扑吗啡诱导的小鼠过度活动（ED50 = 30 mg / kg，口服）的拮抗活性比对甲基苯丙胺致死力的增强作用强11倍，而对15如阿斯吗啡对大鼠的刻板印象抑制作用弱（ED50大于500 mg / kg，口服）为1。另一方面，N-[（1-乙基-2-吡咯烷基）甲基] -2-甲基- 5-甲硫基-2，3-二氢苯并呋喃-7-羧酰胺（30）在对阿扑吗啡诱导的小鼠过度活动的拮抗活性方面表现出与氟哌啶醇相当的经典抗精神病药（ED50 = 0.65 mg / kg，口服）。还讨论了结构-活性关系。
• Benzofuran- and benzopyran-carboxamide derivatives
  申请人：Yoshitomi Pharmaceutical Industries Ltd.

  公开号：US04617314A1

  公开（公告）日：1986-10-14

  Benzofuran- and benzopyran-carboxamide derivatives of the formula: ##STR1## wherein l is 1 or 2; X is hydrogen atom, amino group or halogen atom; Y is --S(O).sub.m --R.sup.3 wherein R.sup.3 is lower alkyl group and m is 0, 1 or 2, or ##STR2## wherein R.sup.4 and R.sup.5 are the same or different and are each hydrogen atom or lower alkyl group; R.sup.1 is hydrogen atom, lower alkyl group, arylthiomethyl group, halogenomethyl group or ##STR3## wherein R.sup.6 and R.sup.7 are the same or different and are each hydrogen atom or lower alkyl group or R.sup.6 and R.sup.7 together with the adjacent nitrogen atom form a hetrocycle; R.sup.2 is hydrogen atom or lower alkyl group; and Z is ##STR4## wherein p is 2 or 3, R.sup.8 and R.sup.9 are the same or different and are each lower alkyl group or R.sup.8 and R.sup.9 together with the adjacent nitrogen atom form a heterocycle, or ##STR5## wherein q is 0 or 1, n is 1 or 2, R.sup.10 is lower alkyl group, lower alkenyl group, lower alkinyl group, aralkyl group or cycloalkyl group and R.sup.11 is hydrogen atom or lower alkyl group, their physiologically acceptable salts or their optical isomers, and a method of preparing same. These compounds are useful as psychotropic and antipsychotic agents.

  苯并呋喃和苯并吡喃-羧酰胺衍生物的化学式如下：##STR1## 其中l为1或2；X为氢原子、氨基或卤原子；Y为--S(O).sub.m --R.sup.3，其中R.sup.3为低碳基且m为0、1或2，或##STR2## 其中R.sup.4和R.sup.5相同或不同，均为氢原子或低碳基；R.sup.1为氢原子、低碳基、芳基硫甲基、卤甲基或##STR3## 其中R.sup.6和R.sup.7相同或不同，均为氢原子或低碳基，或R.sup.6和R.sup.7与相邻的氮原子一起形成杂环；R.sup.2为氢原子或低碳基；Z为##STR4## 其中p为2或3，R.sup.8和R.sup.9相同或不同，均为低碳基或R.sup.8和R.sup.9与相邻的氮原子一起形成杂环，或##STR5## 其中q为0或1，n为1或2，R.sup.10为低碳基、低烯基、低炔基、芳基烷基或环烷基，R.sup.11为氢原子或低碳基，它们的生理上可接受的盐或其光学异构体，以及其制备方法。这些化合物可用作精神药和抗精神病药。
• Naphthamide derivatives
  申请人：Institut National de la Sante et de la Recherche Medicale

  公开号：US05498628A1

  公开（公告）日：1996-03-12

  The new naphthamide derivatives according to the invention are characterized in that they correspond to the general formula (I), ##STR1## where X: represents either a hydrogen atom, or a chlorine or bromine atom, or an amino or aminoalkyl group, an aminosulphamoyl group, a sulphur-containing group such as thiocyanate, alkylthio, alkylsulphinyl or alkylsulphonyl, or a methoxy group, or a nitro group, or a cyano group, or an electron-attracting group; Y: represents an alkyl or alkenyl residue; Z: represents the residues originating from 2-aminomethyl-N-alkylpyrrolidine, 2-aminoethyl-N,N-diethylamine, 2-(aminoethyl)morpholine, 2-aminoethyl-N,N-dibutylamine, 4-amino-N-butylpiperidine or 2-(aminoethyl)pyrrolidine; R: a hydrogen or an OCH.sub.3 substituent. These new derivatives may be employed in the preparation of medicinal products intended for use as an antipsychotic, psychostimulatory, anti-autistic or antidepressant agent, an agent for treating Parkinson's disease or an antihypertensive agent.

  根据本发明的新萘酰胺衍生物的特点在于它们符合以下一般式（I），其中 X：代表氢原子、氯或溴原子、氨基或氨基烷基、氨基磺酰基、硫含基团如硫氰酸根、烷基硫基、烷基亚砜基或烷基砜基、甲氧基、硝基、氰基或电子吸引基团；Y：代表烷基或烯基残基；Z：代表源自2-氨基甲基-N-烷基吡咯烷、2-氨基乙基-N,N-二乙基胺、2-(氨基乙基)吗啉、2-氨基乙基-N,N-二丁基胺、4-氨基-N-丁基哌啶或2-(氨基乙基)吡咯烷的残基；R：氢或OCH3取代基。这些新衍生物可用于制备用作抗精神病、精神刺激、抗自闭症或抗抑郁药物、治疗帕金森病或抗高血压药物的药品。